ArticleInfluenza and other respiratory viruses2026
Meeting Report: Fourth Correlates of Protection for Next Generation Influenza Vaccines.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis report summarizes the discussions and conclusions from the fourth "Correlates of Protection for Next Generation Influenza Vaccines" meeting, which took place in Vienna, Austria, from October 15, 2025, to October 17, 2025.
conclusionDiscussions on influenza virus correlates of protection built on prior meetings, with particular emphasis on challenges introduced by novel vaccine platforms and evolving regulatory expectations. Although established immune markers such as hemagglutination inhibiting (HI) antibodies remain central to influenza vaccine evaluation, this year's discussions highlighted the continued uncertainty and challenges around their generalizability across platforms, populations, and age groups. Regulatory perspectives emphasized the need for strong biological and clinical justification linking immune markers to protection. Overall, the meeting highlighted the importance of continued collaboration among academia, industry, and regulatory agencies to advance the identification and validation of correlates of protection, in alignment with priorities outlined in the 2025 influenza research and development road map for influenza vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.